Skip to main navigation
Keros Therapeutics
About
About Us
Management
Board of Directors
Contact Us
Our Pipeline
Our Pipeline
Our Product Candidates
- KER-050
- KER-047
- KER-012
Our Science
TGF-β Biology & Role in Diseases
Hematology Franchise
- KER-047 for Treatment of Functional Iron Deficiency
- KER-050 for Treatment of Ineffective Hematopoiesis
Pulmonary & Cardiovascular Franchise
- KER-012 for Treatment of Pulmonary and Cardiovascular Disorders
Investors and Media
Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Annual Reports
Corporate Governance
Investor FAQ
Investor Contact
Email Alerts
Careers
Working at Keros
Current Opportunities
Benefits
Folder: About
Folder: Our Pipeline
Folder: Our Science
Folder: Investors and Media
Folder: Careers
Back
About Us
Management
Board of Directors
Contact Us
Back
Our Pipeline
Our Product Candidates
Back
- KER-050
- KER-047
- KER-012
Back
TGF-β Biology & Role in Diseases
Hematology Franchise
Pulmonary & Cardiovascular Franchise
Back
- KER-047 for Treatment of Functional Iron Deficiency
- KER-050 for Treatment of Ineffective Hematopoiesis
Back
- KER-012 for Treatment of Pulmonary and Cardiovascular Disorders
Back
Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Annual Reports
Corporate Governance
Investor FAQ
Investor Contact
Email Alerts
Back
Working at Keros
Current Opportunities
Benefits
banner image

Press Releases

Press Releases

3/3/23
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Read More
3/1/23
Keros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
Read More
2/7/23
Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference
Read More
Follicular_Lymphoma_in_Bone_Marrow image

Keros Therapeutics

1050 Waltham Street, Suite 302
Lexington, MA 02421
+1 (617) 314-6297

Terms of Use

Privacy Notice

Cookie Policy

Expanded Access Policy